- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02129257
Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer (AMALTHEA)
Single-arm Phase II Study of Maintenance Therapy With Aflibercept After First-line Treatment With FOLFIRI Plus Aflibercept in Metastatic Colorectal Cancer Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Statistical hypotheses and sample size calculation:
It is estimated that the progression-free survival (PFS) rate at 1year will be improved from 33% (corresponding to a median PFS of 7.5 months [null hypothesis]) to 47% (corresponding to a median PFS of 11 months [alternative hypothesis]) with the combination of first-line Folinic acid/5-Fluorouracil/Irinotecan (FOLFIRI) plus aflibercept therapy in patients with metastatic colorectal cancer (mCRC). Using the one-stage Fleming's design, in order to reject the null hypothesis in a one-sided test with a type I error of 5% and power 80%, 73 patients will be needed to enter the study.
Analysis population:
- Intent-to-treat (ITT) population: all patients who will have given their informed consent and who will have been correctly registered to the study
- Evaluable population for tumor response: all treated patients, without major protocol deviation, with at least one tumor evaluation while on treatment (except for early disease progression or death) and evaluable for response
- Safety population: the subset of the ITT population that took at least one dose of study medication
Primary analysis:
The primary efficacy parameter will be PFS rate at 1 year and it will be calculated in the ITT population.
Analysis of secondary endpoints:
Response to treatment will be described in a frequency table along with the corresponding percentages and 95% exact confidence intervals.
Kaplan-Meier method will be used to estimate median PFS and overall survival (OS) values and 95% confidence intervals. All of these analyses will be performed in the ITT population. Analysis for objective response rate (ORR) will additionally be presented in the evaluable population for tumor response.
Adverse Events (AEs) of the safety population for the FOLFIRI-aflibercept treatment part and the maintenance therapy will be presented in frequency tables according to grade, along with the corresponding percentages (N, %).
Exploratory endpoints:
Univariate and multivariate Cox regression analyses will also be performed to explore prognostic factors among basic clinicopathological characteristics and evaluated biomarkers, with respect to PFS and OS. Time-to-event distributions for the expression of examined markers will be estimated by Kaplan-Meier method and compared using log-rank test.
Formalin-fixed embedded tumor tissue blocks will be collected from the primaries or metastases for the immunohistochemical and messenger ribonucleic acid (mRNA) study of key angiogenic effectors and regulators, such as: vascular endothelial growth factor A (VEGF A), vascular endothelial growth factor A-121 (VEGFA-121), vascular endothelial growth factor A121b (VEGFA121b), short and long VEGFA isoforms, metalloproteinase inhibitor 3 (TIMP3), vascular endothelial growth factor B (VEGF-B), placental growth factor (PlGF), vascular endothelial growth factor-C (AVEGF-C), Semaphorins, hypoxia-inducible factor 1 (HIF1), vascular endothelial growth factor receptor 1 (VEGFR1), vascular endothelial growth factor receptor 2 (VEGFR2), neuropilin 1 (NRP1), neuropilin 2 (NRP2), thrombospondin 1 (TSP1), thrombospondin 2 (TSP2), angiopoietin-1 (Ang1), Angiopoietin-2 (Ang2), Tie2, interleukin 8 (IL8), CXC chemokine receptor 1 (CXCR1), CXC chemokine receptor 2 (CXCR2)
Pharmacokinetic(PK)/Pharmacodynamic analyses (PD) PK/PD assessments (plasma analytes, plasma free and VEGF-bound aflibercept) will be performed in all registered and treated patients at specified timepoints during both FOLFIRI-aflibercept induction and aflibercept maintenance therapy, to assess the free/bound aflibercept ratio over cycles and the potential correlation with clinical endpoints (safety and efficacy).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Athens, Greece, 11528
- Oncology Section, Dept of Clinical Therapeutics, General Hospital of Athens "Alexandra"
-
Athens, Greece, 14564
- 2nd Dept of Medical Oncology, Agii Anargiri Cancer Hospital
-
Athens, Greece, 14564
- 3rd Dept of Medical Oncology, Agii Anargiri Cancer Hospital
-
Athens, Greece, 15123
- 3rd Dept of Medical Oncology, Hygeia Hospital
-
Athens, Greece, 18547
- 1st Dept of Medical Oncology, Metropolitan Hospital
-
Athens, Greece, 18547
- 2nd Dept of Medical Oncology, Metropolitan Hospital
-
Athens, Greece, 11522
- 2nd Dept of Internal Medicine, Agios Savvas Cancer Hospital
-
Athens, Greece, 11525
- 251 Airforce Hospital
-
Athens, Greece, 11527
- 2nd Dept of Internal Medicine, General Hospital of Athens "Hippokratio"
-
Athens, Greece, 11527
- Oncology Unit, 3rd Dept of Internal Medicine, Athens School of Medicine, Sotiria General Hospital
-
Athens, Greece, 12462
- Division of Oncology, 2nd Dept of Internal Medicine, University Hospital "Attiko"
-
Heraklio, Greece, 71110
- Dept of Medical Oncology, University Hospital of Heraklion
-
Ioannina, Greece, 45500
- Dept of Medical Oncology, Ioannina University Hospital
-
Larissa, Greece, 41334
- Oncology Dept, University Hospital of Larissa
-
Patras, Greece
- Division of Oncology, Dept of Internal Medicine, University Hospital of Patras
-
Thermi, Greece, 57001
- Thermi Clinic S.A.
-
Thessaloniki, Greece, 56429
- Dept of Medical Oncology, Papageorgiou General Hospital
-
-
Mournies
-
Chania, Mournies, Greece, 73300
- Agios Georgios Chania General Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Histologically proven adenocarcinoma of the colon and/or rectum
- Metastatic disease confirmed clinically/radiologically
- Signed written informed consent
- No prior therapy for metastatic disease
- Duly documented inoperable metastatic disease, ie not suitable for complete curative surgical resection
- At least one measurable or evaluable lesion as assessed by Computed Tomography (CT) scan or MRI (Magnetic Resonance Imaging) according to Response Evaluation Criteria In Solid Tumors (RECIST) v1.1
- Age ≥18 years
- Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0-2
Adequate hematological status:
- neutrophils (ANC) ≥1.5x109/L
- platelets ≥100x109/L
- haemoglobin ≥9g/dL
- Adequate renal function: serum creatinine level <1.5 mg/dl and Glomerular Filtration Rate>50 ml/min by Cockroft/Gault formula
Adequate liver function:
- serum bilirubin ≤1.5 x upper normal limit (ULN)
- alkaline phosphatase
- aspartate aminotransferase (AST)
- alanine aminotransferase (ALT) < 5 x ULN
- Proteinuria <2+ (dipstick urinalysis) or ≤1g/24hour
- Regular follow-up feasible
- Baseline evaluations performed before registration: clinical and blood evaluations no more than 2 weeks (14 days) prior to registration, tumor assessment (chest X-ray, CT-scan or MRI, evaluation of non-measurable lesions) no more than 3 weeks (21 days) prior to registration
- First course of treatment planned less than 1 week (7 days) after registration
- For female patients of childbearing potential, negative serum pregnancy test within 1 week (7 days) prior of starting study treatment
- Female patients must commit to using reliable and appropriate methods of contraception until at least three months after the end of study treatment (when applicable). Male patients with a partner of childbearing potential must agree to use contraception in addition to having their partner use another contraceptive method during the trial.
Exclusion Criteria
- Exclusive presence of bone metastasis only
- Uncontrolled hypercalcemia
- Uncontrolled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg despite medical therapy), or history of hypertensive crisis, or hypertensive encephalopathy
- Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy)
- Treatment with any other investigational medicinal product within 28 days prior to study entry
- Other serious and uncontrolled non-malignant chronic disease
- History or presence of Central Nervous System (CNS) metastasis unless adequately treated (e.g. non irradiated CNS metastasis, seizures not controlled with standard medical therapy)
- Gilbert's syndrome
- Intolerance to atropine sulfate or loperamide
- Known dihydropyrimidine dehydrogenase deficiency
- Treatment with Cytochrome P450 3A4 (CYP3A4) inducers unless discontinued > 7 days prior to randomization
- Any of the following in 3 months prior to inclusion: grade 3-4 gastrointestinal bleeding (unless due to resected tumor), treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, or diverticulitis
Other concomitant or previous malignancy, except:
- adequately treated in-situ carcinoma of the uterine cervix
- basal or squamous cell carcinoma of the skin
- cancer in complete remission for >5 years
- Any other serious and uncontrolled non-malignant disease, major surgery or traumatic injury within the last 28 days
- Pregnant or breastfeeding women
- Patients with known allergy to any excipients to study drugs
- History of myocardial infarction and/or stroke or other arterial thrombotic events or pulmonary embolism or unstable angina pectoris within 6 months prior to registration
- Poorly controlled cardiac arrhythmias
- Bowel obstruction
- History of severe tumour bleeding or bleeding disorders
- Poorly controlled anti-coagulation therapy (INR>3.0 on coumadin or heparin compounds)
- Palliative radiation therapy within 4 weeks prior to registration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: FOLFIRI-AFLIBERCEPT
Aflibercept 4 mg/kg administered over 1 hour on Day 1, followed by FOLFIRI regimen.
Treatment will be repeated every 2 weeks.
FOLFIRI regimen: Irinotecan 180 mg/m² intravenous (IV) infusion and folinic acid 400 mg/m² IV infusion followed by: 5-fluorouracil (5-FU) 400 mg/m² IV bolus followed by: 5-FU 2400 mg/m² continuous IV infusion over 46 hours.
FOLFIRI administration will immediately follow the aflibercept one.
In the absence of PD after 6 months of the combination of chemotherapy and aflibercept, the patient will be treated with a maintenance therapy with aflibercept alone until PD or unacceptable toxicities, investigator's decision or patient's refusal of further treatment or death, whichever comes first.
|
Other Names:
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression-Free Survival (PFS) rate at 1 year
Time Frame: Up to 1 year
|
Up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of Objective Response Rate (ORR) defined as the proportion of patients with complete response (CR) or partial response (PR) among all patients, as assessed according to Response Evaluation Criteria for Solid Tumors (RECIST) v1.1
Time Frame: Up to 20 months
|
Response to treatment will be described in a frequency table along with the corresponding percentages and 95% exact confidence intervals.
|
Up to 20 months
|
Evaluation of Overall Survival (OS)
Time Frame: Time interval from registration to the date of death due to any cause assessed up to 60 months
|
Time interval from registration to the date of death due to any cause assessed up to 60 months
|
|
Evaluation of Progression-Free Survival (PFS)
Time Frame: Time interval from registration to the first date of documented progression or death due to any cause assessed up to 60 months
|
Time interval from registration to the first date of documented progression or death due to any cause assessed up to 60 months
|
|
Number of participants with Serious and Non-Serious Adverse Events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0
Time Frame: Up to 40 months
|
Adverse Events of the safety population for the FOLFIRI-aflibercept treatment part and the maintenance therapy will be presented in frequency tables according to grade, along with the corresponding percentages (N,%)
|
Up to 40 months
|
Tumor tissue mRNA levels of VEGFA-121, VEGFA121b, VEGF-B, PlGF, VEGF-C, Semaphorins, HIF1, VEGFR1, VEGFR2, Neuropilins 1,2, Thrombospondin, Angiopoietins 1,2. Predictive significance for response rate, PFS, OS.
Time Frame: Tumor blocks will be collected at baseline
|
Tumor blocks will be collected at baseline
|
|
Steady-state concentration of free Aflibercept and VEGF-bound Aflibercept in plasma. Predictive significance for response rate, PFS, OS.
Time Frame: On day 1 of cycle 1, on day 1 of cycle 3, on day 1 of week 3 of Aflibercept maintenance monotherapy, at the end of treatment, assessed up to 20 months
|
On day 1 of cycle 1, on day 1 of cycle 3, on day 1 of week 3 of Aflibercept maintenance monotherapy, at the end of treatment, assessed up to 20 months
|
|
Enzyme-linked immunosorbent assay (ELISA) plasma concentrations of VEGFA, soluble VEGFR1, soluble VEGFR2, VEGF-B, PlGF, basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF). Predictive significance for response rate, PFS, OS.
Time Frame: On day 1 of cycle 1, on day 1 of cycle 3, on day 1 of week 3 of Aflibercept maintenance monotherapy, at the end of treatment, assessed up to 20 months
|
On day 1 of cycle 1, on day 1 of cycle 3, on day 1 of week 3 of Aflibercept maintenance monotherapy, at the end of treatment, assessed up to 20 months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: George Pentheroudakis, MD, Ass.Prof, Dept of Medical Oncology, Ioannina University Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Protective Agents
- Topoisomerase Inhibitors
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Micronutrients
- Vitamins
- Topoisomerase I Inhibitors
- Antidotes
- Vitamin B Complex
- Hematinics
- Fluorouracil
- Leucovorin
- Irinotecan
- Levoleucovorin
- Folic Acid
- Aflibercept
Other Study ID Numbers
- HE 6A/13
- 2013-002567-26 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Colorectal Cancer
-
Mayo ClinicCompletedMetastatic Colorectal Adenocarcinoma | Metastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Metastatic... and other conditionsUnited States
-
Emory UniversityBristol-Myers Squibb; National Cancer Institute (NCI); National Institutes of...Active, not recruitingColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal CancerUnited States
-
Array Biopharma, now a wholly owned subsidiary...CompletedMetastatic Colorectal Cancer | Advanced Solid Tumors | Advanced or Metastatic Biliary CancerUnited States
-
Hutchison Medipharma LimitedActive, not recruitingMetastatic Colorectal Cancer | Metastatic Colon CancerUnited States, Spain, Japan, Australia, Austria, Belgium, Czechia, Estonia, France, Germany, Hungary, Italy, Poland, United Kingdom
-
Zhejiang Cancer HospitalNot yet recruitingMetastatic Colorectal Cancer | Metastatic Colorectal Adenocarcinoma | CRCChina
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Pancreatic Adenocarcinoma | Stage IV Pancreatic Cancer AJCC v6 and v7 | Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatic Gastroesophageal Junction Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Malignant... and other conditionsUnited States
-
Dana-Farber Cancer InstituteAmerican Cancer Society, Inc.Not yet recruitingMetastatic Colorectal Cancer | Colorectal Cancer | Metastatic Colon CancerUnited States
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer
-
AmgenCompletedCancer | Metastatic Colorectal Cancer | Colorectal Cancer | Rectal Cancer | Metastatic Cancer | Colon Cancer | Oncology
-
Symphogen A/STerminatedCarcinoma | Metastatic Colorectal Cancer | Colorectal Cancer MetastaticUnited States, Spain, Germany, Italy
Clinical Trials on 5-Fluorouracil
-
The Netherlands Cancer InstituteCompleted
-
The Netherlands Cancer InstituteCompleted
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownSquamous Cell Carcinoma of the Head and NeckChina
-
The Cleveland ClinicNational Cancer Institute (NCI)TerminatedActinic Keratosis | Organ or Tissue Transplant; ComplicationsUnited States
-
National Cancer Institute (NCI)CompletedStage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Adenocarcinoma of the Rectum | Adenocarcinoma of the ColonUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TerminatedMucinous Adenocarcinoma of the Rectum | Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal CancerUnited States
-
Peking Union Medical College HospitalRecruitingRectal Cancer | Colon Cancer | Chemotherapy Effect | PTC | Exon MutationChina
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedColorectal Cancer | Metastatic CancerUnited States
-
Singapore National Eye CentreSingapore Eye Research Institute; Nanchang UniversityCompletedGlaucoma | Wound Healing | TrabeculectomySingapore